{
    "clinical_study": {
        "@rank": "13402", 
        "arm_group": [
            {
                "arm_group_label": "Fenofibrate", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received Fenofibrate"
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received Atorvastatin"
            }, 
            {
                "arm_group_label": "Fenofibrate and Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received Fenofibrate and Atorvastatin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate a pharmacokinetic drug interaction between\n      atorvastatin and fenofibrate in healthy subjects."
        }, 
        "brief_title": "CKD-337 Drug Interaction Study", 
        "condition": [
            "Dyslipidemia (Fredrickson Type \u2161a)", 
            "Dyslipidemia (Fredrickson Type \u2161b)"
        ], 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A healthy male volunteer between 19 and 55 years old.\n\n          -  BMI between 18.5 and 27.\n\n          -  Able to participate in the entire trial\n\n          -  Signed the informed consent form prior to study participation.\n\n        Exclusion Criteria:\n\n          -  Clinically significant digestive system, cardiovascular system, respiratory system,\n             endocrine system, hepatic system, renal system\n\n          -  sit SBP < 100mmHg or sit SBP \u2265 150mmHg or sit DBP < 70mmHg or sit DBP \u2265 100mmHg\n\n          -  Have acute infection history within 14 days\n\n          -  Have a allergic disease of need to treat\n\n          -  Have hypersensitivity reactions history for IP or any specific drugs.\n\n          -  AST, ALT or Total bilirubin > UNL * 1.5\n\n          -  Estimated GFR < 60 ml/min\n\n          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,\n             glucose-galactose malabsorption\n\n          -  A heavy smoker (cigarette > 10 cigarettes per day)\n\n          -  A heavy alcohol consumer (alcohol > 140g/week)\n\n          -  A heavy grapefruit consumer (more than 1cup per a day)\n\n          -  Have a history of drug abuse or showed a positive for urine drug test.\n\n          -  Administrated IP within 60 days prior to screening\n\n          -  Rhabdomyolysis include of having a history or family history of genetic muscle\n             diseases\n\n          -  Positive for HIV antibody, HBsAg, HCV antibody test\n\n          -  Previously donate whole blood within 60 days or component blood within 30 days\n\n          -  Subject takes ethical drug or herbal medicine within 30 days\n\n          -  Clinically significant laboratory test result\n\n          -  An impossible one who participates in clinical trial by investigator's decision\n             including other reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066207", 
            "org_study_id": "146DDI13024"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Fenofibrate", 
                    "Fenofibrate and Atorvastatin"
                ], 
                "intervention_name": "Fenofibrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Fenofibrate and Atorvastatin"
                ], 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fenofibrate", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "wooseong.huh@samsung.com", 
                "last_name": "Wooseong Huh, M.D., Ph.D.", 
                "phone": "+82-2-3410-3443"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Fenofibrate and Atorvastatin in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "wooseong.huh@samsung.com", 
            "last_name": "Wooseong Huh, M.D., Ph.D.", 
            "phone": "+82-2-3410-3443"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Wooseong Huh, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AUCt, Cmax,ss of fenofibric acid and atorvastatin", 
            "safety_issue": "No", 
            "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066207"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Tmax,ss, Cmin,ss, t1/2, CL/Fss, Vd/Fss, %swing, Cav, %fluctuation", 
            "safety_issue": "No", 
            "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}